2023 LIVER Symposium
The NCSCG Board and Meeting Planning Committee are proud to announce the 8th Annual NCSCG hybrid Liver Symposium, being held January 21, 2023, both online and in-person at the Hotel Nia in Menlo Park, CA!
The symposium will provide a unique opportunity to receive a comprehensive update in chronic liver disease from nationally renowned faculty. The educational lectures at this symposium will focus on important advances presented at the annual American Association for the Study of Liver Disease (AASLD) Meeting and/or in recent publications. You will also have ample opportunity to interact with colleagues, our expert faculty members, and industry representatives.
Click on the link above for complete conference and registration information. Please feel free to contact the NCSCG with any questions or comments by sending an email to firstname.lastname@example.org.
The 2023 NCSCG Liver Planning Committee
Robert Wong, MD, MS; NCSCG Vice President
Mikhail Alper, PA-C; NCSCG APP Committee Member
Nghiem Ha, MD; NCSCG Lead Fellow
Allison Kwong, MD; Board Member
Marina Roytman, MD, FACP; Board Member
Kidist Yimam, MD; Board Member
This activity has been designed to meet the educational needs of physicians, physician assistants and nurse practitioners involved in the care of patients with chronic liver disease (CLD).
Statement of Need
The goal of this program is to provide important clinical and scientific data on the management of chronic liver disease (CLD).
Upon completion of this symposium, participants should be better able to:
Describe new data as it pertains to the implications and options for patients and their continued care
Apply updated guidelines for care for chronic liver related diseases
Discuss future directions of therapeutics, diagnostics, and technology in the management of liver diseases
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Northern California Society for Clinical Gastroenterology (NCSCG). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of the Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Northern California Society for Clinical Gastroenterology. RMCHCS is accredited by NMMS to provide continuing medical education for physicians.
RMCHCS designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn up to 5.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities sponsored/provided by Rehoboth McKinley Christian Health Care Services (RMCHCS) are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material.
Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff, and reviewers of the Northern California Society for Clinical Gastroenterology (NCSCG) and Rehoboth McKinley Christian Health Care Services (RMCHCS) have no relationships to disclose.
This activity is supported by educational grants from Janssen Biotech, Inc., Mallinckrodt Pharmaceuticals, and Salix Pharmaceuticals.